The basis of allotment for the ₹ 1,900 crore Urban Company IPO will be announced today, 15 September 2025. Investors can check the IPO allotment status through the official websites of the NSE, BSE, or the IPO’s registrar, MUFG Intime India.
Urban Company IPO is a book-building issue of ₹1,900 crore, consisting of a fresh issue of ₹472 crore and an offer for sale (OFS) of ₹1,428 crore.
The bidding window was open from September 10, 2025, to September 12, 2025, during which the IPO received a total subscription of 108.98x. The price band is set between ₹98 and ₹103 per share.
Book-running lead managers for the IPO are Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, Goldman Sachs (India) Securities Private Limited, and JM Financial Limited, while MUFG Intime India Private Limited (Link Intime) is the registrar for the IPO.
[12 September, 2025, End of the day]
Investor Category |
Subscription (Times) |
Qualified Institutional Buyers (QIBs) |
147.35 |
Non-Institutional Investors |
77.82 |
Retail Individual Investors (RIIs) |
41.49 |
Employees |
42.55 |
Total |
108.98 |
The company will not receive any proceeds from the OFS component and will directly go to the selling shareholders.
The net proceeds from the fresh issue will be used towards
As of 15 September 2025, Urban Company IPO’s GMP stood at ₹68.5. The estimated listing price is ₹171.5, i.e., a 66.50% gain per share over the upper price band.
Source: Investorgain Media Report dated 15 September, 2025 Disclaimer: The GMP (Grey Market Premium) price is an unauthenticated market related news and has no discernible basis. The same quoted above is as per news appeared in the media report and is for information purposes only. The investor shall do their own study/research before using the same for taking any decision to invest. We neither engage in, trade, or deal in the grey market nor we recommend or endorse trading in the grey market. |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.